1Choueiri TK,Mayer EL,Je Y,et al.Congestive heart failure risk in patients with breast cancer treated with Bevacizumab[J].J Clin Oncol,2011,doi:10.1200/JCO.2010.31.9129.
2Ranpura V,Hapani S,Wu S.Treatment-related mortality with Bevacizumab in cancer patients:A meta-analysis[J].JAMA,2011,305(5):487-494.
3Hayes DF.Bevacizumab treatment for solid tumors,Boon or bust?[J] JAMA,2011,305(5):506-508.
4Saltz LB,Clarke S,Diaz-Rubio E,et al.Bevacizumab in combination with Oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer; A randomized phase Ⅲ study[J].J Clin Oncol,2008,26(12):2013-2019.
2Shojaei F.Anti-angiogenesis therapy in cancer:current challenges and future perspectives[J].Cancer Lett,2012,320(2):130-137.
3Cuzick J,Sestak I,Cella D,et al.Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence:a retrospective analysis of the ATAC trial[J].Lancet Oncol,2008,9(12):1143-1148.
5Zhang L,Ge W,Hu K,et al. Endostar down-regulates HIF-1 and VEGF expression and enhances the radiore- sponse to human lung adenocarcinoma cancer cells [J]. Mol Biol Rep , 2012, 39(1) : 89-95.
6Curran WJ, Paulus R, Langer C J, et al. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer:randomized phase 111 trial RTOG 9410 [J]. J Natl Cancer Inst,2011,103(19) : 1452-1460.
7Diaz-Rubio E, Gomez-Espana A, Massuti B, et al. First- line XELOX plus beva cizumab followed by XELOX plus bevacizumab or singleagent bevacizumab as main- tenance therapy in patients with metastatic colorectal cancer:the phase IU MACRO TTD study [J]. Oncologist, 2012,17(1) : 15-25.
8Wang J, Xiao J, Wei X, et al. Circulating endothelial ceils and tumor blood volume as predictors in lung can- cer [J]. Cancer Sci,2013,104(4) :445-452.
